Reading the DNA of fetuses is the next frontier of the genome revolution. Do you really want to know the genetic destiny of your unborn child?
Antonio RegaladoFollow @twitterapi
Senior Editor, Business
I am the business editor of MIT Technology Review. I look for stories about how technology is changing business. Before joining MIT Technology Review in July 2011, I lived in São Paulo, Brazil, where I wrote about science, technology, and politics in Latin America for Science and other publications. From 2000 to 2009, I was the science reporter at the Wall Street Journal and later a foreign correspondent.
Antonio Regalado's Stories
Putting genome data into the public domain advances science, but nearly all of it can be linked to someone.
By reviving lost species, a new company could put a warm and fuzzy face on advanced reproductive engineering.
Advances in genetic engineering have some biologists convinced they’ll re-create extinct species.
An ultrathin electrode spun from a single carbon fiber can record neurons in living animals.
J. Craig Venter may have just started a race to discover alien life on the Red Planet.
Kari Stefansson says his genetic research company has shown that older fathers pass many more DNA mutations to their children.
A study of whether embryonic stem cells could cure spinal-cord injury suffered from high costs, dim prospects.
A small biotech firm is the second company to start human tests of embryonic stem-cell therapy.
After years of controversy, a therapy based on human embryonic stem cells is finally being tested in humans. The treatment holds out hope to paralyzed people, but at how great a risk?